Related Experiment Video
Updated: Aug 22, 2026
Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses
Published on: March 29, 2017
Reduning injection alleviated LPS-induced ARDS via multi-target regulation by modulating inflammation and immune
Si-Wen Hui1, Qi-Meng Zhu1, Zi-Zhou Liu1
1School of Chinese Materia Medica, School of Medical Technology, Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China.
Background:
Acute respiratory distress syndrome (ARDS) is an acute respiratory failure syndrome arising from non-cardiogenic pulmonary edema, characterized by limited therapeutic options and a poor prognosis, underscoring an urgent need for effective treatments. Reduning injection (RDN) is a traditional Chinese medicine formulation widely used in clinical practice for treating respiratory tract infections. However, its specific role and underlying mechanism in ARDS remain to be fully elucidated.
Purpose:
This study aimed to examine the multi-target protective effects of RDN against ARDS and elucidate its underlying mechanisms.
Study Design And Methods:
A lipopolysaccharide (LPS)-induced ARDS model was established to evaluate the therapeutic potential of RDN. A multifaceted experimental approach, encompassing flow cytometry, immunofluorescence, the integration target fishing technique of thermal-solvent (TS) proteomics and affinity chromatography (AC), Western blot, real-time PCR, immunohistochemistry, scRNA-seq analysis, molecular docking, and molecular dynamics, was adopted to uncover the therapeutic mechanism of RDN in ARDS.
Results:
RDN alleviated the progression of ARDS by improving alveolar barrier function and reducing histopathological lung damage. The underlying mechanisms involved the inhibition of the MAPK, NF‑κB, and NLRP3 pathways, which led to the decreasing of release for key inflammatory cytokines (IL‑6, IL‑1β, and TNF‑α). It also attenuated pulmonary infiltration of macrophages and neutrophils and modulated the Treg/Th17 balance, thereby maintaining pulmonary immune homeostasis. Furthermore, employing the target fishing technique, we identified folliculin (Flcn), integrin alpha-V (Itgav), and phospholipase C-β3 (Plcb3) as direct intracellular targets of RDN, which was further supported by various chemical biological methods. LC‑MS/MS analysis revealed that components of RDN entered the blood and lungs, among which isochlorogenic acid A (IAA) and genipin 1-gentiobioside (GG) were identified as bioactive components that directly bound to Flcn, Itgav, and Plcb3, respectively.
Conclusion:
RDN alleviated LPS-induced ARDS by modulating inflammatory and immune responses via multi-target regulation of Flcn, Itgav, and Plcb3, thereby inhibiting the NLRP3, NF-κB, and MAPK pathways.
